Sirpa Leppa
@LeppaSM
Professor of Oncology, lymphoma doctor, chair of the NLG & NLG LBCL WG
We've kicked-off our first research training program for 2025. This week we've gathered a cohort of 20 young hematologists to undertake Clinical Research Training in Hematology in Milan. Over four days, they will hear from the brightest minds, discussing key topics shaping the…
Täyden kympin ilta eilen! Roosa nauha tanssi tähtien kanssa upean tuloksen. Kertalahjoituksina lahjoitettiin illan aikana huikeat 1,7 miljoonaa euroa. Lisäksi yli 2 500 henkilöä lupautui kuukausilahjoittajiksi❤️Kiitos kaikille! roosanauha.syopasaatio.fi/2024/10/28/roo… #roosanauha #syöpätutkimus
Happy to share our study on distinct cancer-associated fibroblasts (CAFs), their spatial architecture, and impact on survival in #Hodgkin #lymphoma just released in @Hemasphere_EHA at doi.org/10.1002/hem3.7…
Here we introduce a simple 3-point frailty score for older Hodgkin patients to inform clinical decisions and prospective trials for older patients. Happy to participate in this Norwegian initiative! Early View | Haematologica haematologica.org/article/view/1…
Excellent educational overview of the management of DLBCL as well as self-assessment case by Raúl Cordoba at the @EHA_Hematology - HKSH Hematology Tutorial in Lymphoid Malignancies 2025. ”The first bullet is the best bullet”
@EHA_Hematology is joining the Hong Kong Society of Hematology (HKSH) to organize the #Hematology Tutorial on Lymphoid Malignancies. 📆 5-6 April 2025 📍 Hong Kong 🇭🇰 #lymsm
Online Now: Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics dlvr.it/TJnywK
Applications for #TRTH2026 are now open! Are you an early-career researcher in translational hematology? The EHA-ASH TRTH program provides a unique opportunity to enhance your research skills with guidance from leading international experts. 🔹 Applications open today, March 15!…
👍I fully agree. #EHACRTH is an excellent opportunity to learn to conduct clinical trials in hematology, network internationally and get new friends.
#EHACRTH a privilege to be involved & many colleagues to celebrate & learn from @EHA_Hematology @DrRaulCordoba @_DrCP @LeppaSM #AmyKirkwood @jangeissler @kate_orf @ABarrettHaem & many others Further work to be done in June & September Highly recommended for all involved
Syöpätautien erikoislääkäri ja TYKSn tulosryhmäjohtaja Sirkku Jyrkkiölle myönnettiin juuri lääkäripäivien avajaisissa Max Oker-Blom palkinto ansiokkaasta lääkärijohtamisesta. Oikein meni. Lämpimät onnittelut Sirkku! #lääkäripäivät @DuodecimFi @Laakariliitto
Tonight, Santa will embark on his journey from Lapland to around the world as a true ambassador of goodwill, bringing Christmas cheer to millions of homes. Happy Holidays! ❤️🎅🏻
I could not agree more
#ISHL13 Sarah Rutherford to present the data of trial N-AVD vs BV-AVD in older patients 60+ with cHL #lymsm #geriheme To me, this should be the new 🆕 SoC in older patients. I hope @EMA_News approves soon 🔜 this approach
R/R DLBCL in Older Adults 2024 ashpublications.org/blood/article/…
Our Nordic NLPHL results (Finland, Denmark and Sweden), presented by @glimelius
Greetings from ISHL13: Happy to see this update: Simply excellent survival data for elderly HL patients in response to N-AVD.
Update on older adults in S1826 @DrAEvens #ISHL13 (T077): - 99 pts age >60y, median f/u now 2.1 yrs - 2-yr PFS 89% N-AVD (64% BV-AVD) - 2-yr OS 96% N-AVD (85% BV-AVD) - 16% NRM in BV-AVD arm (!!!) vs 6% N-AVD is SOC in older adults with AS cHL. #lymsm onlinelibrary.wiley.com/doi/full/10.10…
Just in time for #ISHL13 a comprehensive review on Hodgkin lymphoma biology and implications for translational research is now available @TrendsMolecMed, masterfully authored by Ralf Küppers @unidue #SFB1530 cell.com/trends/molecul…